Global Lungs Cancer Market Research Report – Segmentation By Route of Administration (Oral, Intravenous, Intramuscular, Subcutaneous, Parenteral, Topical, Others); By Type (Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Lung Carcinoid Tumour); By Treatment Type (Chemotherapy, Immunotherapy, Radiology, Targeted Therapy, Surgery, Laser Surgery); By End-User (Hospitals, Clinics, Pharmacies); Region – Size, Share, Growth Analysis | Forecast (2024 – 2030)
Published: 2024 - January
Report Code: IM-16132
Format:
Region: Global
Chapter 1. GLOBAL LUNGS CANCER MARKET – Scope & Methodology
1.1. Market Segmentation
1.2. Scope, Assumptions & Limitations
1.3. Research Methodology
1.4. Primary Sources
1.5. Secondary Sources
Chapter 2. GLOBAL LUNGS CANCER MARKET– Executive Summary
2.1. Market Size & Forecast – (2023 – 2030) ($M/$Bn)
2.2. Key Trends & Insights
2.2.1. Demand Side
2.2.2. Supply Side
2.4. Attractive Investment Propositions
2.5. COVID-19 Impact Analysis
Chapter 3. GLOBAL LUNGS CANCER MARKET– Competition Scenario
3.1. Market Share Analysis & Company Benchmarking
3.2. Competitive Strategy & Development Scenario
3.3. Competitive Pricing Analysis
3.4. Supplier-Distributor Analysis
Chapter 4. GLOBAL LUNGS CANCER MARKET - Entry Scenario
4.1. Regulatory Scenario
4.2. Case Studies – Key Start-ups
4.3. Customer Analysis
4.5. PESTLE Analysis
4.4. Porters Five Force Model
4.4.1. Bargaining Power of Suppliers
4.4.2. Bargaining Powers of Customers
4.4.3. Threat of New Entrants
4.4.4. Rivalry among Existing Players
4.4.5. Threat of Substitutes
Chapter 5. GLOBAL LUNGS CANCER MARKET- Landscape
5.1. Value Chain Analysis – Key Stakeholders Impact Analysis
5.2. Market Drivers
5.3. Market Restraints/Challenges
5.4. Market Opportunities
Chapter 6. GLOBAL LUNGS CANCER MARKET– By Route Of Administration
-
- Oral
- Intravenous
- Intertumoral
- Intramuscular
- Subcutaneous
- Parenteral
- Topical
- Others
Chapter 7. GLOBAL LUNGS CANCER MARKET– By Type
-
- Small Cell Lung Cancer
- Non-Small Cell Lung Cancer
- Lung Carcinoid Tumour.
Chapter 8. GLOBAL LUNGS CANCER MARKET– By Treatment
-
- Chemotherapy
- Immunotherapy
- Radiology
- Targeted Therapy
- Surgery
- Laser Surgery
Chapter 9. GLOBAL LUNGS CANCER MARKET – By End User
9.1. Hospitals
9.2. Clinics
9.3. Pharmacies
Chapter 10. GLOBAL LUNGS CANCER MARKET, By Geography – Market Size, Forecast, Trends & Insights
10.1. North America
10.1.1. By Country
10.1.1.1. U.S.A.
10.1.1.2. Canada
10.1.1.3. Mexico
10.1.2. By Type
10.1.3. By Treatment Type
10.1.4. By Route Of Administration
10.1.5. End User
10.1.6. Countries & Segments - Market Attractiveness Analysis
10.2. Europe
10.2.1. By Country
10.2.1.1. U.K.
10.2.1.2. Germany
10.2.1.3. France
10.2.1.4. Italy
10.2.1.5. Spain
10.2.1.6. Rest of Europe
10.2.2. By Product Type
10.2.3. By Treatment Type
10.2.4. By Route Of Adminsitration
10.2.5. End User
10.2.6. Countries & Segments - Market Attractiveness Analysis
10.3. Asia Pacific
10.3.2. By Country
10.3.2.2. China
10.3.2.2. Japan
10.3.2.3. South Korea
10.3.2.4. India
10.3.2.5. Australia & New Zealand
10.3.2.6. Rest of Asia-Pacific
10.3.2. By Product Type
10.3.3. By Treatment Type
10.3.4. By Route Of Administration
10.3.5. Molecule Type
10.3.6. Countries & Segments - Market Attractiveness Analysis
10.4. South America
10.4.3. By Country
10.4.3.3. Brazil
10.4.3.2. Argentina
10.4.3.3. Colombia
10.4.3.4. Chile
10.4.3.5. Rest of South America
10.4.2. By Product Type
10.4.3. By Treatment Type
10.4.4. By Route Of Administration
10.4.5. Molecule Type
10.4.6. Countries & Segments - Market Attractiveness Analysis
10.5. Middle East & Africa
10.5.4. By Country
10.5.4.4. United Arab Emirates (UAE)
10.5.4.2. Saudi Arabia
10.5.4.3. Qatar
10.5.4.4. Israel
10.5.4.5. South Africa
10.5.4.6. Nigeria
10.5.4.7. Kenya
10.5.4.10. Egypt
10.5.4.10. Rest of MEA
10.5.2. By Product Type
10.5.3. By Treatment Type
10.5.4. By Route Of Administration
10.6.5. Molecule Type
10.5.6. Countries & Segments - Market Attractiveness Analysis
Chapter 11. GLOBAL LUNGS CANCER MARKET – Company Profiles – (Overview, Product Portfolio, Financials, Strategies & Developments)
11.1. Pfizer
11.2. AstraZeneca
11.3. Merck (MSD)
11.4. Bristol-Myers Squibb
11.5. Eli Lilly and Company
11.6. Boehringer Ingelheim
11.7. Novartis
11.8. Merck KGaA (EMD Serono)
11.9. AbbVie
11.10. Takeda
11.11. Astellas Pharma
11.12. F. Hoffmann-La RocheGlaxoSmithKline
11.13. Johnson & Joson
11.14. Sanofi
11.15 Amgen
Download Sample
Choose License Type
2500
4250
5250
6900
Frequently Asked Questions
The Lungs Cancer Market was valued at USD 83.39 billion and is projected to reach a market size of USD 127.05 billion by the end of 2030. Over the forecast period of 2024-2030, the market is projected to grow at a CAGR of 6.20%.
High Incidence rate of Lungs Cancer, Highly effective presence of drugs are the key drivers for lung cancer market.
Based on Treatment, the Lungs Cancer Market is segmented into Chemotherapy, Immunotherapy, Targeted therapy and radiology, Surgery, laser Surgery.
North America is the most dominant region for the Lungs Cancer Market.
Hoffmann-La Roche Ltd, Novartis AG, Pfizer, Bristol-Myers Squibb Co, Eli Lilly and Company and Sanofi are the key players operating in the Lungs Cancer Market.
